References
- Akiyama T, Shibata T, Yoshinaga H, Kuhara T, Nakajima Y, Kato T, et al. A Japanese case of betaureidopropionase deficiency with dysmorphic features. Brain & development 2017;39:58-61. https://doi.org/10.1016/j.braindev.2016.08.001
- van Kuilenburg AB, Dobritzsch D, Meijer J, Meinsma R, Benoist JF, Assmann B, et al. Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta 2010;1802:639-48. https://doi.org/10.1016/j.bbadis.2010.03.013
- Nakajima Y, Meijer J, Dobritzsch D, Ito T, Meinsma R, Abeling NG, et al. Clinical, biochemical and molecular analysis of 13 Japanese patients with beta-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation [corrected]. J Inherit Metab Dis 2014;37:801-12. https://doi.org/10.1007/s10545-014-9682-y
- van Kuilenburg AB, Dobritzsch D, Meijer J, Krumpel M, Selim LA, Rashed MS, et al. ss-ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 2012;1822:1096-108. https://doi.org/10.1016/j.bbadis.2012.04.001
- Lee JH, van Kuilenburg AB, Abeling NG, Vasta V, Hahn SH. A Korean Case of beta-Ureidopropionase Deficiency Presenting with Intractable Seizure, Global Developmental Delay, and Microcephaly. JIMD Rep 2015;19:117-21.
- Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci 2003;60:321-36. https://doi.org/10.1007/s000180300027
- Connolly GP, Simmonds HA, Duley JA. Pyrimidines and CNS regulation. Trends Pharmacol Sci 1996;17:106-7. https://doi.org/10.1016/0165-6147(96)20001-X
- Van Kuilenburg AB, Stroomer AE, Van Lenthe H, Abeling NG, Van Gennip AH. New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 2004;379:119-24. https://doi.org/10.1042/bj20031463
- Shinohara T, Harada M, Ogi K, Maruyama M, Fujii R, Tanaka H, et al. Identification of a G proteincoupled receptor specifically responsive to beta-alanine. The Journal of biological chemistry 2004;279:23559-64. https://doi.org/10.1074/jbc.M314240200
- Schmieden V, Kuhse J, Betz H. A novel domain of the inhibitory glycine receptor determining antagonist efficacies: further evidence for partial agonism resulting from self-inhibition. Molecular pharmacology 1999;56:464-72. https://doi.org/10.1124/mol.56.3.464
- Shu J, Lv X, Jiang S, Zhang Y, Zhang C, Meng Y, et al. Genetic analysis of the UPB1 gene in two new Chinese families with beta-ureidopropionase deficiency and the carrier frequency of the mutation c.977G>A in Northern China. Childs Nerv Syst 2014;30:2109-14. https://doi.org/10.1007/s00381-014-2541-1
- Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997;38:1062-8. https://doi.org/10.1111/j.1528-1157.1997.tb01194.x
- Ficker DM, So EL, Shen WK, Annegers JF, O'Brien PC, Cascino GD, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998;51:1270-4. https://doi.org/10.1212/WNL.51.5.1270
- Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 2005;46 Suppl 11:54-61.
- Lamberts RJ, Thijs RD, Laffan A, Langan Y, Sander JW. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia 2012;53:253-7. https://doi.org/10.1111/j.1528-1167.2011.03360.x